Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.
CD8+ T cells
TLR7 ligand
cancer immunotherapy
type I interferon
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
03
11
2018
revised:
15
03
2019
accepted:
22
03
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
31
5
2019
Statut:
epublish
Résumé
TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a novel synthetic agonist with exquisite specificity for TLR7. We found that intravenously administered SC1 mediates systemic release of type I interferon, but not of proinflammatory cytokines such as TNFα and IL6, and results in activation of circulating immune cells. Tumors of SC1-treated mice have brisk immune cell infiltrates and are polarized towards a Th1 type signature. Intratumoral CD8
Identifiants
pubmed: 31143525
doi: 10.1080/2162402X.2019.1601480
pii: 1601480
pmc: PMC6527305
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1601480Références
Nature. 2001 Oct 18;413(6857):732-8
pubmed: 11607032
J Am Acad Dermatol. 2004 May;50(5):722-33
pubmed: 15097956
J Immunol. 2005 Feb 1;174(3):1259-68
pubmed: 15661881
Blood. 2006 Nov 15;108(10):3253-61
pubmed: 16868248
J Interferon Cytokine Res. 2008 Apr;28(4):253-63
pubmed: 18439103
Curr Opin Immunol. 2008 Aug;20(4):389-95
pubmed: 18652893
J Immunotoxicol. 2009 Dec;6(4):257-65
pubmed: 19848448
Cancer Immunol Immunother. 2010 Dec;59(12):1877-1884
pubmed: 20820775
Cancer Res. 2010 Nov 15;70(22):9031-40
pubmed: 21045153
Immunity. 2010 Dec 14;33(6):955-66
pubmed: 21130004
Cancer Res. 2011 Aug 1;71(15):5123-33
pubmed: 21697281
J Clin Invest. 2012 Feb;122(2):575-85
pubmed: 22251703
Am J Hematol. 2012 Oct;87(10):953-6
pubmed: 22718533
Cancer Res. 2013 Aug 1;73(15):4629-40
pubmed: 23722543
Drug Discov Today. 2014 Apr;19(4):379-82
pubmed: 24012797
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Immunotherapy. 2014;6(10):1085-95
pubmed: 25428647
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Vaccine. 2015 Jun 26;33(29):3360-6
pubmed: 26027906
Clin Pharmacol Ther. 2015 Oct;98(4):369-80
pubmed: 26044169
Cancer Immunol Immunother. 2015 Oct;64(10):1229-39
pubmed: 26091797
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Nat Rev Drug Discov. 2015 Sep;14(9):603-22
pubmed: 26228631
Oncotarget. 2016 Oct 25;7(43):70223-70231
pubmed: 27602959
Oncoimmunology. 2016 May 31;5(7):e1189051
pubmed: 27622045
Cancer Immunol Res. 2017 Aug;5(8):642-653
pubmed: 28637878
Leukemia. 2017 Oct;31(10):2278
pubmed: 28751765
Sci Transl Med. 2017 Sep 13;9(407):null
pubmed: 28904226
J Natl Cancer Inst. 1966 Apr;36(4):641-5
pubmed: 4160686
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
Cancer Res. 1993 Nov 1;53(21):5176-80
pubmed: 8221654